miR-375-3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor-1β.
hepatocyte nuclear factor-1β
laryngeal squamous cell carcinoma
microRNA-375-3p
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
24
03
2019
accepted:
21
05
2020
entrez:
1
9
2020
pubmed:
31
8
2020
medline:
31
8
2020
Statut:
ppublish
Résumé
Laryngeal squamous cell carcinoma (LSCC) is one of the most frequently diagnosed head and neck cancers worldwide. Increasing evidence suggests that microRNAs (miRNAs/miRs) regulate the progression of tumorigenesis and the malignant behaviors of cancer cells. The aim of this study was to investigate the function and underlying mechanism of miR-375-3p in LSCC. The expression of miR-375-3p in LSCC tissues and cells was detected using reverse transcription-quantitative PCR. The effects of miR-375-3p on the malignant phenotype of LSCC cells was determined using the Cell Counting Kit-8 assay and flow cytometry. The targets of miR-375-3p were predicted using the miRDB database and confirmed by the luciferase reporter assay. The results of the present study demonstrated that miR-375-3p was downregulated in LSCC tissues and cell lines. Furthermore, overexpression of miR-375-3p significantly suppressed the proliferation and cell cycle progression of LSCC cells. Overexpression of miR-375-3p also increased LSCC cell apoptosis. Mechanistical analysis indicated that miR-375-3p bound the 3'-untranslated region of the hepatocyte nuclear factor 1β (HNF1β) and decreased its expression in LSCC cells. Consistent with the role of HNF1β in glucose metabolism, overexpression of miR-375-3p significantly inhibited glucose consumption and lactate production in LSCC cells. Transfection with HNF1β notably reversed the inhibitory effect of miR-375-3p on the proliferation of LSCC cells. Collectively, these results indicate the tumor suppressive role of miR-375-3p in LSCC via HNF1β, suggesting that miR-375-3p may serve as a potential target in the treatment of LSCC.
Identifiants
pubmed: 32863913
doi: 10.3892/ol.2020.11941
pii: OL-0-0-11941
pmc: PMC7436894
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Informations de copyright
Copyright: © Chang et al.
Références
Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7296-7304
pubmed: 30468474
Rev Physiol Biochem Pharmacol. 2016;171:1-38
pubmed: 27457236
Cell Physiol Biochem. 2018;50(1):342-352
pubmed: 30282067
Folia Biol (Praha). 2018;64(3):71-83
pubmed: 30394265
Semin Liver Dis. 2015 Feb;35(1):3-11
pubmed: 25632930
Onco Targets Ther. 2014 Apr 05;7:525-33
pubmed: 24741319
J Cell Physiol. 2018 Aug;233(8):5574-5588
pubmed: 29521426
Annu Rev Biochem. 2010;79:351-79
pubmed: 20533884
Oral Oncol. 2015 Apr;51(4):321-31
pubmed: 25677760
J Cancer Educ. 2013 Sep;28(3):454-7
pubmed: 23728993
Mol Carcinog. 2015 Jan;54(1):35-49
pubmed: 24105991
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Int J Oncol. 2019 Feb;54(2):689-701
pubmed: 30535502
J Cell Biochem. 2018 Oct 9;:
pubmed: 30302801
Pharmacol Res. 2015 Jul;97:104-21
pubmed: 25958353
Cancer Biol Ther. 2019;20(6):826-836
pubmed: 30907227
Thorac Cancer. 2015 Jan;6(1):17-24
pubmed: 26273330
Auris Nasus Larynx. 2019 Feb;46(1):106-113
pubmed: 29843929
Pediatr Nephrol. 2016 May;31(5):707-14
pubmed: 26160100
J Pathol. 2011 Jan;223(2):102-15
pubmed: 21125669
Braz J Otorhinolaryngol. 2018 Sep - Oct;84(5):566-573
pubmed: 28823696
J Hematol Oncol. 2017 Feb 20;10(1):52
pubmed: 28219405
Biomed Pharmacother. 2014 Mar;68(2):149-54
pubmed: 24055400
Clin Otolaryngol. 2017 Feb;42(1):104-114
pubmed: 27185184
Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):629-639
pubmed: 27923456
Histopathology. 2018 Jun;72(7):1102-1114
pubmed: 29266325
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Oncotarget. 2015 Oct 13;6(31):30704-14
pubmed: 26375553
Auris Nasus Larynx. 2019 Aug;46(4):583-592
pubmed: 30454973
Int J Gynecol Cancer. 2009 Apr;19(3):471-9
pubmed: 19407577
EMBO Mol Med. 2017 Jun;9(6):852
pubmed: 28572088
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Histol Histopathol. 2009 Nov;24(11):1479-86
pubmed: 19760597
Ann Pathol. 1999 Apr;19(2):153
pubmed: 10349487
Cancer Sci. 2010 Nov;101(11):2309-15
pubmed: 20726859
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Cell Physiol. 2019 Jul;234(7):10002-10017
pubmed: 30537109
Biochem Cell Biol. 2018 Dec;96(6):752-760
pubmed: 29874469
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Oncotarget. 2015 Sep 22;6(28):26002-17
pubmed: 26318292
Oncol Lett. 2020 Jul;20(1):774-784
pubmed: 32566004
Biochem Biophys Res Commun. 2012 Oct 19;427(2):254-60
pubmed: 22995297